1955 Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy. (September 2015) - Yamashita, T.; Masuda, N.; Yamamoto, N.; Kondo, N.; Bando, H.; Akiyoshi, S.; Ohtani, S.; Takano, T.; Inoue, K.; Fujisawa, T.; Ishiguro, H.; Nakayama, H.; et al.